Taken together, the results obtained by integrating the GeCK screening, multiple RCC cohort, and experimental validation data enabled us to highlight JMJD6 as an independent predictive biomarker that is also a therapeutic vulnerability for RCC. The gene discussed is JMJD6; the disease is renal cell carcinoma.